Kim Heylen | Managing Director, Labo Nuytinck
Kim Heylen obtained a PhD and did a post-doc at UGent. She was promotor of 6 PhD students, and author of >50 A1 peer reviewed papers, as well as advocated for science communication and post-doc career development during her academic career. In 2016 she (finally) switched to Industry and joined Biocartis as biobank manager. After 2 years Kim joined Eurofins Food, Feed and Water as business unit manager, where she re-organized the lab operations. Next, Kim took up a global Innovations Director role at INVE, leading teams in Belgium, Italy and Thailand. She again re-organized the department and implemented a formalized innovation pipeline. Early 2022 Kim joined the family-owned Labo Nuytinck, part of Anacura. Energized by the value driven, long-term approach of the company, she agreed to take up the role of Managing Director from June 1st 2023 onwards.
As an independent laboratory for clinical biology, with strong local roots, Labo Nuytinck is a fixture in primary and secondary care in East and West Flanders, with a site in Evergem and Bruges.
Since 1985, we have been supporting healthcare providers with our medical analyzes in all phases of the care process: from prevention and diagnosis to therapy and monitoring. We do this through a combination of the most advanced technologies, a strong team of clinical biologists, a lot of attention to integrity and scientific foundations and a corporate culture of sustainability and continuous innovation.Together with AnaBioTec, which focuses on drug development, we form the family group anacura.
Our mission? Sensible and high-quality care, together with you.
Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | |
|
© Copyright 2020 by Hyphen Projects